https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43081 Tue 13 Sep 2022 12:19:26 AEST ]]> Controversies in the management of gastrointestinal stromal tumors https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17494 Sat 24 Mar 2018 08:04:10 AEDT ]]> KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20630 Sat 24 Mar 2018 07:55:48 AEDT ]]>